Table 2.
Pharmacokinetic parameters of LMT-28 after intravenous and oral administration at doses of 5 mg/kg in male BALB/c mice (n = 4)
| Parameters | Intravenous (i.v) | Oral (p.o.) |
|---|---|---|
| Dose (mg/kg) | 5 | 5 |
| Tmax (h) | - | 0.80±0.67 |
| Cmax (ng/mL) | - | 137±100 |
| t1/2 (h) | 1.37±0.29 | 1.13±0.27 |
| CL (L/h/kg) | 8.66±4.51 | - |
| Vss (L/kg) | 12.9±4.66 | - |
| AUC8h (h·ng/mL) | 661±253 | 292±202 |
| AUC∞ (h·ng/mL) | 677±264 | 302±209 |
| MRT (h) | 1.58±0.32 | 1.9±0.55 |
| F (%) | - | 38.2 |
Data represent mean±standard deviation.
Tmax, the time to reach a peak concentration; Cmax, peak plasma concentration; t1/2, terminal elimination half-life; CL, clearance; Vss, distribution volume at steady state; AUC8h, area under the plasma concentration-time curve values of LMT-28 during 8 h; AUC∞, able to cover approximately 96.7% of the total AUC; MRT, mean residence time; F, bioavailability.